Wednesday, May 2, 2007
FDA expands antidepressant warning to young adults
The Food and Drug Administration proposed labeling changes that would expand a warning now on all antidepressants. The current language applies only to children and adolescents. The expanded warning would apply to adults 18-24 during the first month or two of treatment with the drugs, the FDA said.
The proposed labeling changes also would note that studies have not shown this increased risk in adults older than 24, and that adults 65 and older taking antidepressants have a decreased risk of suicidal thoughts and behavior, it said.
http://www.cnn.com/2007/HEALTH/05/02/antidepressants.suicide.ap/index.html
Monday, April 30, 2007
Older schizophrenia drug works, costs less: study
The American Journal of Psychiatry study concluded that the older, first-generation antipsychotic drug perphenazine was less expensive and as effective as newer medications such as AstraZeneca Plc's Seroquel and Eli Lilly and Co.'s Zyprexa.
Funded by the U.S. National Institutes of Health, the $42.6 million study suggests doctors should consider the use of older antipsychotics as a first choice for patients with schizophrenia, a group of psychotic diseases marked by delusions and hallucinations.
"There could be a very useful role -- from a clinical and cost-effectiveness standpoint -- for greater utilization of some older-generation medications," said Dr. Jeffrey Lieberman, a psychiatrist at Columbia University Medical Center and the study's lead author.
Metformin slows antipsychotic drug weight gain
"Weight gain was shown recently to be the most important factor leading to noncompliance with these very effective medications," study leader Dr. David J. Klein, from Cincinnati Children's Hospital Medical Center, Ohio, told Reuters Health.
Atypical antipsychotics generally have fewer side effects than some of the older antipsychotic drugs. Some of the drugs in this newer class of antipsychotics commonly prescribed include risperidone, sold as Risperdal; quetiapine, sold as Seroquel; and olanzapine, sold as Zyprexa.
Primary text: American Journal of Psychiatry, December 2006
Fish oils, vitamins, herbs helpful for depression
A number of nutrients, including polyunsaturated fatty acids, St. John's Wort and several B vitamins, have the potential to influence mood by increasing the absorption of chemical messengers in the brain, Dr. Dianne Volker of the University of Sydney in Chippendale and Jade Ng of Goodman Fielder Commercian in North Ryde, New South Wales note in the journal Nutrition and Dietetics.
There is a wealth of epidemiological, experimental and circumstantial evidence to suggest that fish and the oils they contain, in particular omega-3 polyunsaturated fatty acid, are protective against depression, Volker and Ng write. They point out that the balance between omega-3 and omega-6 may also be important, given that the latter can prevent the body from absorbing the former.
READ MORE @ Reuters
Antipsychotic drugs linked to sexual function
In a cross-sectional analysis, Dr. Oliver D. Howes and colleagues from the Institute of Psychiatry, London, UK, examined rates of sexual dysfunction and hypogonadism in 103 patients with schizophrenia or schizoaffective disorder stabilized on antipsychotic medication for at least 6 months. They were compared with 62 normal controls recruited from primary care attendees and with 57 subjects recruited from a sexual dysfunction clinic.
READ MORE @ Reuters
Primary text: J Clin Psychiatry 2007;68:361-367.
Drug Trials For Painkiller Addicts
The National Institute on Drug Abuse is launching its first large scale Prescription Opiate Addiction Treatment Study at 12 sites across the country, including the NYU/Bellevue primary-care clinic. The drug trials will test the effectiveness of buprenorphone/naloxone tablets - marketed as Suboxone - to break patients' addictions to painkillers such as Vicodin and OxyContin. The tablets will be accompanied by different levels of drug-abuse counseling, a key aspect of the study.
READ MORE @ New York Post
JNJ's Janssen closer to new Invega OK
The Committee for Human Medicinal Products in the European Union gave the drug a positive recommendation for approval. The drug will likely be approved in the European Union based on the positive recommendation. Also Friday, the U.S. Food and Drug Administration approved the drug as a long-term treatment for schizophrenia. It had already been approved as a short-term treatment.
READ MORE @ Hemscott.com
Patients Diagnosed Schizophrenic and Bipolar to boost Seroquel Sales
For instance, Seroquel, marketed by AstraZeneca, is only FDA approved to treat acute manic episodes associated with bipolar I disorder and schizophrenia, and yet it is one of the most widely prescribed drugs in the world.
Astra reports that over 16 million patients have taken Seroquel since it came on the market in 1997, and the drug had sales of close to three and a half billion dollars in 2006, according to SEC filings.
READ MORE @ Lawyers & Settlements
Vigilance Still Necessary for Atypical Antipsychotics
The overall medication plan should address the major side effect concerns of each patient, said Daniel E. Casey, M.D., of the Oregon Health and Science University in Portland, in a presentation here at the U.S. Psychiatric and Mental Health Congress regional extension.
“Choose your medications with the principle ‘first do no harm’ in mind,” he said. “Chose the drug with the lowest side effect profile.”
READ MORE @ from Psychiatric Times
Primary source: U.S. Psychiatric and Mental Health Congress
Johnson n Johnson schizophrenia drug gets wider US approval
The drug, a longer-acting version of J&J’s Risperdal, was approved in December to treat acute, or short-term, schizophrenia.
READ MORE @ at Reuters